The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacokinetics (PK) of blinatumomab and its clinical implications.
Benjamin Wu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Youssef Hijazi
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Andreas Wolf
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Christian Brandl
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Yu-Nien Sun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Min Zhu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen